SHR-1826

SHR-1826

English Name: SHR-1826

SHR-1826 is an antibody-drug conjugate (ADC) targeting c-Met. It is currently under development by Suzhou Suncadia Biopharmaceuticals.

Mechanism of Action: The mechanism of action is currently undefined but classified as a c-Met inhibitor. ADCs typically work by combining the specificity of an antibody for a tumor-associated antigen (in this case, c-Met) with a cytotoxic drug. The antibody binds to the cancer cell, and the ADC is internalized, releasing the cytotoxic drug inside the cell to kill it.

Clinical Trials: SHR-1826 is being evaluated in several Phase 1 and Phase 2 clinical trials for various advanced solid tumors, including:

• NCT06703177: A Phase 1/2 study evaluating SHR-1826 in combination with other antitumor therapies in subjects with advanced solid tumors. This study is currently recruiting.
• NCT06094556: An open-label Phase 1 study of SHR-1826 monotherapy in patients with advanced solid tumors. This study is currently recruiting.
• NCT06844474: A Phase 2 study evaluating the safety, tolerability, and efficacy of SHR-1826 in combination with other anti-cancer treatments in patients with non-small cell lung cancer (NSCLC). This study is currently recruiting.
• NCT06935175: A Phase 2 study of SHR-1826 monotherapy or in combination with immunotherapy in patients with advanced hepatocellular carcinoma. This study is not yet recruiting.
• NCT06915142: A Phase 2 study on the safety, tolerability, and efficacy of HRS-7058 (another agent) in combination with antitumor drugs, including SHR-1826, in subjects with solid tumors. This study is not yet recruiting.